Identified Employee Surveys: Where Do We Go From Here?

Scherbaum, Charles A.; Saari, Lise M.

doi:10.1111/j.1754-9434.2011.01381.x

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from 12 published papers and reports [4][5][6][7][8][9][10][11][12][13][14][15] that satisfied the search criteria on eight drugs were digitized [16] and the data consisted of temporal profiles for the two primary biomarkers, i.e. FPG and HbA1c after monotherapy treatment.…”

Section: Translational Model For Hba1cmentioning

confidence: 99%

Simple pharmacometric tools for oral anti‐diabetic drug development: competitive landscape for oral non‐insulin therapies in type 2 diabetes

Samtani

2010

Biopharm & Drug Disp

View full text Add to dashboard Cite

The objectives were to develop a translational model that will help select doses for Phase-3 trials based on abbreviated Phase-2 trials and understand the competitive landscape for oral anti-diabetics based on efficacy, tolerability and ability to slow disease progression. Data for eight anti-diabetics with temporal profiles for fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) from 12 publications were digitized. The monotherapy data consisted of FPG and HbA1c profiles that were modeled using a transit compartment model. Evaluation of the competitive landscape utilized HbA1c literature data for 11 drugs. For the safety metric, tolerability issues with anti-diabetic drug classes were tabulated. For disease progression, the coefficient of failure method was used for assessing data from two long-term trials. The transit rate constants were remarkably consistent across 12 trials and represent system-specific/drug-independent parameters. The competitive landscape analysis showed that the primary efficacy metric fell into two groups of DeltaHbA1c: >0.8% or approximately 0.8%. On the safety endpoints, older agents showed some tolerability issues while the new agents were relatively safe. Among the different drug classes, only the thiazolidinediones appeared to slow disease progression but may also increase heart failure risk. In conclusion, the ability of system-specific parameters to predict HbA1c provides a tool to predict the expected efficacy profile from abbreviated dose-finding trials. To be commercially viable, new drugs should improve DeltaHbA1c by about 0.8% or more and possess safety profiles similar to newer anti-diabetic agents. Thus, this study proposes a suite of simple yet powerful tools to guide type-2-diabetes drug development.

show abstract